Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer
FTD/TPI plus bevacizumab showed a consistent and manageable safety profile across first- and later-line mCRC treatment, including in vulnerable patients. Hematologic TEAEs were mostly reversible with appropriate management.
Authors
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- L. Roby
- Julien Taı̈eb (ORCID: https://orcid.org/0000-0002-9955-4753)
- Gábor Liposits (ORCID: https://orcid.org/0000-0002-8204-3949)
- Gerald W. Prager (ORCID: https://orcid.org/0000-0002-7854-7781)
- Fortunato Ciardiello (ORCID: https://orcid.org/0000-0002-4661-5540)
- Elizabeth Calleja
- Marwan Fakih (ORCID: https://orcid.org/0000-0002-6554-5488)
- Nadia Amellal (ORCID: https://orcid.org/0000-0002-6171-6729)
- Thierry André (ORCID: https://orcid.org/0000-0002-5103-7095)
- Mei Liu (ORCID: https://orcid.org/0000-0003-0851-3858)
- Eric Van Cutsem (ORCID: https://orcid.org/0000-0002-6372-1230)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Saint-Antoine (FR)
- City of Hope (US)
- Taiho Oncology (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Servier (France) (FR)
- Vall d'Hebron Institute of Oncology (ES)
- Medical University of Vienna (AT)
- KU Leuven (BE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.3389/fonc.2024.1506075
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- Merck KGaA
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- Seagen
- Eisai
- Astellas Pharma
- Servier
- Ipsen
- Genentech
- Chugai Pharmaceutical
- Takeda Oncology
- Daiichi Sankyo Europe